1. Home
  2. UBFO vs MOLN Comparison

UBFO vs MOLN Comparison

Compare UBFO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Security Bancshares

UBFO

United Security Bancshares

HOLD

Current Price

$10.63

Market Cap

183.4M

Sector

Finance

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.15

Market Cap

151.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
UBFO
MOLN
Founded
1987
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
183.4M
151.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
UBFO
MOLN
Price
$10.63
$4.15
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
31.9K
5.9K
Earning Date
01-22-2026
03-05-2026
Dividend Yield
4.60%
N/A
EPS Growth
N/A
N/A
EPS
0.70
N/A
Revenue
$48,283,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$999.99
P/E Ratio
$14.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.32
$3.36
52 Week High
$11.05
$5.35

Technical Indicators

Market Signals
Indicator
UBFO
MOLN
Relative Strength Index (RSI) 60.46 49.36
Support Level $10.35 $3.97
Resistance Level $11.05 $4.27
Average True Range (ATR) 0.26 0.17
MACD 0.02 -0.00
Stochastic Oscillator 62.50 53.65

Price Performance

Historical Comparison
UBFO
MOLN

About UBFO United Security Bancshares

United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: